Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in IOVA — Iovance Biotherapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to IOVA Full portfolio

Position in IOVA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$9,165,820
+$585,182 QoQ
Shares Held
2,611,345
-16.9% QoQ
Ownership
0.585%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in IOVA Over Time

Shares Held

Position Value (USD)

Derivatives in IOVA

reported options exposure · as of Mar 31, 2026
CallValue
$2,664,090
CallShares
759,000
PutValue
$1,727,622
PutShares
492,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. IOVA ranks #96 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in IOVA

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,664,090 759,000
2026-03-31 $9,165,820 2,611,345
2026-03-31 $1,727,622 492,200
2025-12-31 $1,796,886 658,200
2025-12-31 $1,658,748 607,600
2025-12-31 $8,580,638 3,143,091
2025-09-30 $8,290,189 3,820,364
2025-09-30 $1,404,424 647,200
2025-09-30 $1,265,327 583,100
2025-06-30 $738,568 429,400
2025-06-30 $992,784 577,200
2025-06-30 $7,075,371 4,113,588
2025-03-31 $5,770,233 1,732,803
2025-03-31 $1,002,663 301,100
2025-03-31 $2,247,750 675,000
2024-12-31 $3,203,460 432,900
2024-12-31 $8,092,669 1,093,604
2024-12-31 $7,377,060 996,900
2024-09-30 $6,166,413 656,700
2024-09-30 $3,076,164 327,600
2024-09-30 $9,613,820 1,023,836
2024-06-30 $2,499,834 311,700
2024-06-30 $3,398,876 423,800
2024-06-30 $1,950,929 243,258
2024-03-31 $5,572,320 376,000
2024-03-31 $16,464,974 1,110,997
2024-03-31 $9,028,344 609,200
2023-12-31 $3,149,562 387,400
2023-12-31 $2,325,455 286,034
2023-12-31 $2,766,639 340,300
2023-09-30 $1,770,564 389,135
2023-09-30 $2,431,065 534,300
2023-09-30 $1,605,695 352,900
2023-06-30 $2,066,240 293,500
2023-06-30 $9,394,506 1,334,447
2023-06-30 $1,271,424 180,600
2023-03-31 $1,982,084 324,400
2023-03-31 $681,876 111,600
2023-03-31 $21,214,109 3,472,031
2022-12-31 $1,100,358 172,200
2022-12-31 $835,812 130,800
2022-12-31 $14,658,927 2,294,042
2022-09-30 $680,180 71,000
2022-09-30 $4,136,950 431,832
2022-09-30 $1,973,480 206,000
2022-06-30 $27,840,936 2,521,824
2022-06-30 $3,050,352 276,300
2022-06-30 $1,131,600 102,500
2022-03-31 $7,277,715 437,100
2022-03-31 $2,251,179 135,206

Report a Problem

Category
Description
Email (optional, for follow-up)